In addition, the results of the current study indicate that injection of a low dose of an anti-VCAM-1 neutralizing antibody alleviated Ang II-induced hypertension, attenuated arterial remodeling, and improved vascular dysfunction, but only to a modest degree when compared with injection of a high dose of an anti-VCAM-1 neutralizing antibody (0.2 mg). This evidence concerns the gene AGT and hypertensive disorder.